Moleculin Biotech Inc buy Roth Capital
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 15.12.26. The prediction end date can be changed by Roth_Capital at any time.Moleculin Biotech (Symbol: MBRX) is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing a broad range of innovative cancer treatments. With a diversified portfolio of drug candidates targeting difficult-to-treat cancers, including leukemia, lung, and pancreatic tumors, MBRX leverages cutting-edge scientific research and expertise to develop drugs that aim to provide improved patient outcomes. The company's innovative approach includes utilizing metabolic inhibitors, immune-globulin-like transcript 3 (ILT3) inhibitors, and STAT3 inhibitors as key weapons in the fight against cancer. As Moleculin Biotech advances its drug candidates through clinical trials, it holds the promise of bringing novel cancer therapies to market, potentially improving the lives of cancer patients globally.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Moleculin Biotech Inc | - | - |
| iShares Core DAX® | -1.764% | 2.259% |
| iShares Nasdaq 100 | -1.632% | -0.193% |
| iShares Nikkei 225® | -2.451% | 4.086% |
| iShares S&P 500 | -2.252% | -0.151% |
Comments by Roth_Capital for this prediction
In the thread Moleculin Biotech Inc diskutieren